%0 Journal Article %A Veerappan, Sundaram G. %A Healy, Martin %A Walsh, Bernard J. %A O'Morain, Colm A. %A Daly, Jacqueline %A Ryan, Barbara M. %D 2019 %T Adalimumab Therapy Has a Beneficial Effect on Bone Metabolism in Patients with Crohn's Disease. %U https://repository.rcsi.com/articles/journal_contribution/Adalimumab_Therapy_Has_a_Beneficial_Effect_on_Bone_Metabolism_in_Patients_with_Crohn_s_Disease_/10766276 %2 https://repository.rcsi.com/ndownloader/files/19278731 %K Adalimumab %K Chron's Disease %K Osteoporosis %K Bone Metabolism. %K Anatomy %X

BACKGROUND: Infliximab has been shown to have beneficial effects on bone metabolism in patients with Crohn's disease (CD) although as yet the exact mechanisms have not been fully elucidated.

AIM: To evaluate the impact of adalimumab therapy on bone metabolism using a combined in vivo and in vitro model.

METHODS: Parathyroid hormone, vitamin D, bone formation markers, bone resorption marker, pro-inflammatory cytokines, anti-inflammatory cytokines, osteoprotegerin, and sRANKL were measured in control patients and pre- and post-treatment with adalimumab in CD patients. The effect of control patients' and pre- and post-treatment CD patients' sera on human osteoblasts (hFOB 1.19) in vitro cell viability and differentiation was also analyzed.

RESULTS: There was a significant increase in bone formation markers osteocalcin (P < 0.05) and procollagen type 1 N-terminal propeptide (P < 0.01) at 1 and 3 months post-treatment. Moreover, there was a sustained but not significant fall in serum CTx, a bone resorption marker. No significant change was seen over time with other parameters measured. Serum from CD patients pre-treated with adalimumab showed increased osteoblast viability compared with that of post-treated patients at 6 months (P = 0.002) and controls. However, post-adalimumab treatment sera at 6 months appeared to increase osteoblast differentiation (P = 0.001), which is likely to be important in new bone formation.

CONCLUSIONS: This first study evaluating the role of adalimumab as a possible bone protector in Crohn's disease patients has shown that similar to infliximab, adalimumab has complex and potentially beneficial effects on bone metabolism.

%I Royal College of Surgeons in Ireland